drugset / Trial / NCT06968988
Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.
Timeline
- Start
- 2026-01-05
- Primary completion
- 2029-02-12
- Completion
- 2034-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Zanzalintinib | Small molecule | 20 mg | Oral |
| Subject | Zanzalintinib | Small molecule | 40 mg | Oral |
| Subject | Zanzalintinib | Small molecule | 60 mg | Oral |